Bishal Gyawali, MD, PhD

News

Why Overall Survival Should Be The Oncology Trial Endpoint

Author:: Bishal Gyawali, MD, PhD

Publish date: January 28, 2025

Disease progression and progression-free survival are arbitrary benchmarks that in no way imply that a patient’s subjective experience.

Read More

Opinion

New Drug Approvals Are the Wrong Metric for Cancer Policy

Author:: Bishal Gyawali, MD, PhD

Publish date: March 20, 2024

How should we define success in cancer policy — what should the endpoint be?

Read More